{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:20Z","timestamp":1793332160625,"version":"4.5.0"},"reference-count":50,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Cervical cancer (CC) is one of the most common cancer types affecting women globally. Cervical cancer is largely associated with human papillomavirus infections; however, approximately 5% to 11% of CC cases are non-human papillomavirus virus-related. Malawi has the second highest CC prevalence and mortality rate worldwide.\nObjective: This study investigated the burden of rare genetic variants in genes associated with CC among Malawian women.\nMethods: Ethical approval was obtained from the National Health Science Research committee on 28 August 2023. Whole-genome sequencing was performed on 20 Malawian CC patients, followed by variant discovery and annotation using the Genome Analysis Toolkit and Ensembl\u2019s Variant Effector Predictor. Test for Rare Variants Against Public Database was performed on qualifying variants using 76 156 genomes from the Genome Aggregation database as controls. Bonferroni correction was applied to account for multiple testing.\nResults: We identified 372 genes with a significant burden of rare variants (p &lt; 0.05), including FAT1 (p = 0.0003), a known tumour suppressor gene associated with CC. After Bonferroni correction (p &lt; 6.7\u00d710\u221205), significance shifted to HTR3B, EPHA8, ABCC2, and SEC23B genes linked to various cancer types.\nConclusion: A significant burden of rare variants associated with CC was observed in known genes associated with lung, ovarian and osteosarcoma cancers, suggesting an increased population risk of developing CC and other cancers among Malawian women that needs further investigation.\nWhat this study adds: The high burden of rare variants in the FAT1 gene, and a significant rare\u2013variant burden in other cancer associated genes, supports a broader CC genetic risk and possible novel roles requiring further exploration.<\/jats:p>","DOI":"10.4102\/ajlm.v15i1.3073","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:50:15Z","timestamp":1778673015000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Burden of rare genetic variants in genes associated with cancer among Malawian cervical cancer patients"],"prefix":"10.4102","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0568-5743","authenticated-orcid":false,"given":"Samuel D.","family":"Gwayi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00khnq787","id-type":"ROR","asserted-by":"publisher"}],"name":"Kamuzu University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-8714","authenticated-orcid":false,"given":"Tamiwe","family":"Tomoka","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina, Lilongwe Project, Lilongwe, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-2047","authenticated-orcid":false,"given":"Emile R.","family":"Chimusa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/049e6bc10","id-type":"ROR","asserted-by":"publisher"}],"name":"Northumbria University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-2908","authenticated-orcid":false,"given":"George","family":"Fedoriw","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina, Lilongwe Project, Lilongwe, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-7528","authenticated-orcid":false,"given":"Benjamin","family":"Kumwenda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00khnq787","id-type":"ROR","asserted-by":"publisher"}],"name":"Kamuzu University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref0","unstructured":"Denny L. Cervical cancer: Prevention and treatment. Discov Med. 2012;14(75):125\u2013131."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Janicek MF, Averette HE. Cervical cancer: Prevention, diagnosis, and therapeutics. CA Cancer J Clin. 2001;51(2):92\u2013114; quiz 115\u2013118. https:\/\/doi.org\/10.3322\/canjclin.51.2.92","DOI":"10.3322\/canjclin.51.2.92"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tanaka LF, Schriefer D, Radde K, Schauberger G, Klug SJ. Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study. PLoS One. 2021;16(7):e0253801. https:\/\/doi.org\/10.1371\/journal.pone.0253801","DOI":"10.1371\/journal.pone.0253801"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rodr\u00edguez F, Limones-Gonz\u00e1lez JE, Mendoza-Almanza B, et al. Understanding cervical cancer through proteomics. Cells. 2021;10(8):1854. https:\/\/doi.org\/10.3390\/cells10081854","DOI":"10.3390\/cells10081854"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Small W, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404\u20132412. https:\/\/doi.org\/10.1002\/cncr.30667","DOI":"10.1002\/cncr.30667"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 2020;8(2):e191\u2013e203. https:\/\/doi.org\/10.1016\/S2214-109X(19)30482-6","DOI":"10.1016\/S2214-109X(19)30482-6"},{"key":"ref7","unstructured":"Stang A, Gianicolo E. Age standardization of epidemiological frequency measures. Dtsch \u00c4rztebl Int. 2025;122(14):387\u2013392."},{"key":"ref8","unstructured":"Kamiza AB, Incidence and risk factors associated with cervical cancer in sub-Saharan Africa: A systematic review. ARCH Women Health Care. 2020;3(1):1\u20137."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gerstl S, Lee L, Nesbitt RC, et al. Cervical cancer screening coverage and its related knowledge in southern Malawi. BMC Public Health. 2022;22(1):295. https:\/\/doi.org\/10.1186\/s12889-022-12547-9","DOI":"10.1186\/s12889-022-12547-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Msyamboza KP, Mwagomba BM, Valle M, Chiumia H, Phiri T. Implementation of a human papillomavirus vaccination demonstration project in Malawi: Successes and challenges. BMC Public Health. 2017;17(1):599. https:\/\/doi.org\/10.1186\/s12889-017-4526-y","DOI":"10.1186\/s12889-017-4526-y"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"De Freitas AC, Gurgel APAD, Chagas BS, Coimbra EC, Do Amaral CMM. Susceptibility to cervical cancer: An overview. Gynecol Oncol. 2012;126(2):304\u2013311. https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.047","DOI":"10.1016\/j.ygyno.2012.03.047"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Shi Y, Li L, Hu Z, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat Genet. 2013;45(8):918\u2013922. https:\/\/doi.org\/10.1038\/ng.2687","DOI":"10.1038\/ng.2687"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: New concepts and clinical implications. Cancer Med. 2018;7(10):5217\u20135236. https:\/\/doi.org\/10.1002\/cam4.1501","DOI":"10.1002\/cam4.1501"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jia M, Han J, Hang D, et al. HLA-DP is the cervical cancer susceptibility loci among women infected by high-risk human papillomavirus: Potential implication for triage of human papillomavirus-positive women. Tumour Biol. 2016;37(6):8019\u20138025. https:\/\/doi.org\/10.1007\/s13277-015-4673-7","DOI":"10.1007\/s13277-015-4673-7"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Burk RD, Chen Z, Saller C, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378\u2013384. https:\/\/doi.org\/10.1038\/nature21386","DOI":"10.1038\/nature21386"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Masuda T, Low SK, Akiyama M, et al. GWAS of five gynecologic diseases and cross-trait analysis in Japanese. Eur J Hum Genet. 2020;28(1):95\u2013107. https:\/\/doi.org\/10.1038\/s41431-019-0495-1","DOI":"10.1038\/s41431-019-0495-1"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rasnic R, Linial N, Linial M. Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations. Sci Rep. 2020;10:13462. https:\/\/doi.org\/10.1038\/s41598-020-70494-0","DOI":"10.1038\/s41598-020-70494-0"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Bodmer W, Tomlinson I. Rare genetic variants and the risk of cancer. Curr Opin Genet Dev. 2010;20(3):262\u2013267. https:\/\/doi.org\/10.1016\/j.gde.2010.04.016","DOI":"10.1016\/j.gde.2010.04.016"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lenkova K, Khusainova R, Minyazeva R, et al. Germline variants in proto-oncogenes and tumor suppressor genes in women with cervical cancer. Biomedicines. 2024;12(11):2454. https:\/\/doi.org\/10.3390\/biomedicines12112454","DOI":"10.3390\/biomedicines12112454"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Auer PL, Lettre G. Rare variant association studies: Considerations, challenges and opportunities. Genome Med. 2015;7(1):16. https:\/\/doi.org\/10.1186\/s13073-015-0138-2","DOI":"10.1186\/s13073-015-0138-2"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gudmundsson S, Singer-Berk M, Watts NA, et al. Variant interpretation using population databases: Lessons from gnomAD. Hum Mutat. 2022;43(8):1012\u20131030. https:\/\/doi.org\/10.1002\/humu.24309","DOI":"10.1002\/humu.24309"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Riccio C, Jansen ML, Thal\u00e9n F, Koliopanos G, Link V, Ziegler A. Assessment of the functionality and usability of open-source rare variant analysis pipelines. Brief Bioinform. 2025;26(1):bbaf044. https:\/\/doi.org\/10.1093\/bib\/bbaf044","DOI":"10.1093\/bib\/bbaf044"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Tagliaferro SS, Zejnelagic A, Farrugia R, Wettinger SB. Comparison of DNA extraction methods for samples from old blood collections. BioTechniques. 2021;70(5):243\u2013250. https:\/\/doi.org\/10.2144\/btn-2020-0113","DOI":"10.2144\/btn-2020-0113"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047\u20133048. https:\/\/doi.org\/10.1093\/bioinformatics\/btw354","DOI":"10.1093\/bioinformatics\/btw354"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal. 2011;17(1):10\u201312. https:\/\/doi.org\/10.14806\/ej.17.1.200","DOI":"10.14806\/ej.17.1.200"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u20131303. https:\/\/doi.org\/10.1101\/gr.107524.110","DOI":"10.1101\/gr.107524.110"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows\u2013Wheeler transform. Bioinformatics. 2010;26(5):589\u2013595. https:\/\/doi.org\/10.1093\/bioinformatics\/btp698","DOI":"10.1093\/bioinformatics\/btp698"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4","DOI":"10.1186\/s13059-016-0974-4"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Saint Pierre A, G\u00e9nin E. How important are rare variants in common disease? Brief Funct Genomics. 2014;13(5):353\u2013361. https:\/\/doi.org\/10.1093\/bfgp\/elu025","DOI":"10.1093\/bfgp\/elu025"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden testing of rare variants identified through exome sequencing via publicly available control data. Am J Hum Genet. 2018;103(4):522\u2013534. https:\/\/doi.org\/10.1016\/j.ajhg.2018.08.016","DOI":"10.1016\/j.ajhg.2018.08.016"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Etymologia: Bonferroni correction. Emerg Infect Dis. 2015;21(2):289. https:\/\/doi.org\/10.3201\/eid2102.ET2102","DOI":"10.3201\/eid2102.ET2102"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sherman BT, Hao M, Qiu J, et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216\u2013W221. https:\/\/doi.org\/10.1093\/nar\/gkac194","DOI":"10.1093\/nar\/gkac194"},{"key":"ref33","unstructured":"Chen M, Sun X, Wang Y, et al. FAT1 inhibits the proliferation and metastasis of cervical cancer cells by binding \u03b2-catenin. Int J Clin Exp Pathol. 2019;12(10):3807\u20133818."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Chen ZG, Saba NF, Teng Y. The diverse functions of FAT1 in cancer progression: Good, bad, or ugly? J Exp Clin Cancer Res. 2022;41(1):248. https:\/\/doi.org\/10.1186\/s13046-022-02461-8","DOI":"10.1186\/s13046-022-02461-8"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Tzvetkov MV, Meineke C, Oetjen E, Hirsch-Ernst K, Brockm\u00f6ller J. Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene. 2007;386(1):52\u201362. https:\/\/doi.org\/10.1016\/j.gene.2006.08.002","DOI":"10.1016\/j.gene.2006.08.002"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Chen JR, Huang MS, Lee YC, Lin MH, Yang YF. Potential clinical value of 5-hydroxytryptamine receptor 3C as a prognostic biomarker for lung cancer. J Oncol. 2021;2021(1):1901191. https:\/\/doi.org\/10.1155\/2021\/1901191","DOI":"10.1155\/2021\/1901191"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Zhan D, Wang X, Zheng Y, et al. Integrative dissection of 5-hydroxytryptamine receptors-related signature in the prognosis and immune microenvironment of breast cancer. Front Oncol. 2023;13:1147189. https:\/\/doi.org\/10.3389\/fonc.2023.1147189","DOI":"10.3389\/fonc.2023.1147189"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Liu X, Xu Y, Jin Q, et al. EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget. 2016;7(15):20801. https:\/\/doi.org\/10.18632\/oncotarget.8018","DOI":"10.18632\/oncotarget.8018"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Campa D, M\u00fcller P, Edler L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer. 2012;131(12):2920\u20132928. https:\/\/doi.org\/10.1002\/ijc.27567","DOI":"10.1002\/ijc.27567"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhou H, Yang S, Su D. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cell Biochem Funct. 2021;39(2):277\u2013286. https:\/\/doi.org\/10.1002\/cbf.3577","DOI":"10.1002\/cbf.3577"},{"key":"ref41","unstructured":"LENG Jie QG. Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis. China Oncol. 2023;33(2):152\u2013161."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Yehia L, Jindal S, Komar AA, Eng C. Non-canonical role of cancer-associated mutant SEC23B in the ribosome biogenesis pathway. Hum Mol Genet. 2018;27(18):3154\u20133164. https:\/\/doi.org\/10.1093\/hmg\/ddy226","DOI":"10.1093\/hmg\/ddy226"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Kalyvianaki K, Panagiotopoulos AA, Malamos P, et al. Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression. Steroids. 2019;142:100\u2013108. https:\/\/doi.org\/10.1016\/j.steroids.2019.01.006","DOI":"10.1016\/j.steroids.2019.01.006"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72(4):399\u2013409. https:\/\/doi.org\/10.1002\/pros.21442","DOI":"10.1002\/pros.21442"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chen B, Wang Y, Tang W, et al. Association between PPAR\u03b3, PPARGC1A, and PPARGC1B genetic variants and susceptibility of gastric cancer in an Eastern Chinese population. BMC Med Genomics. 2022;15(1):274. https:\/\/doi.org\/10.1186\/s12920-022-01428-0","DOI":"10.1186\/s12920-022-01428-0"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wirtenberger M, Tchatchou S, Hemminki K, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis. 2006;27(11):2201\u20132208. https:\/\/doi.org\/10.1093\/carcin\/bgl067","DOI":"10.1093\/carcin\/bgl067"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Li Y, Li Y, Wedr\u00e9n S, et al. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13(1):R10. https:\/\/doi.org\/10.1186\/bcr2817","DOI":"10.1186\/bcr2817"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Kalm\u00e1r A, P\u00e9terfia B, Holl\u00f3si P, et al. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer. 2015;15(1):736. https:\/\/doi.org\/10.1186\/s12885-015-1687-x","DOI":"10.1186\/s12885-015-1687-x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Qin Q, Ramesh S, Gomez-Salazar M, et al. CNTNAP4 signaling regulates osteosarcoma disease progression. NPJ Precis Oncol. 2023;7(1):1\u201313. https:\/\/doi.org\/10.1038\/s41698-022-00344-x","DOI":"10.1038\/s41698-022-00344-x"}],"container-title":["African Journal of Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/3073\/3458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:51:23Z","timestamp":1778673083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/3073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/ajlm.v15i1.3073","relation":{},"ISSN":["2225-2002","2225-2010"],"issn-type":[{"value":"2225-2002","type":"print"},{"value":"2225-2010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"a3073"}}